Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Inclusion Criteria: * Patients 18 years and older * Diagnosed with normal tension glaucoma based on the following: * IOP ≤ 21mmHg * Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma * Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year * Open angles assessed by gonioscopy * Have been on latanoprost monotherapy for at least 6 weeks Exclusion Criteria: If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * Other forms of secondary glaucoma. * Patients with abnormal anterior segment examination other than cataract will be excluded from the study. * Patients who have had incisional surgery for glaucoma (eg: MIGs). * Patients with refractory CME or CME persisting 3 months or more. * Children, cognitive impaired and critically ill subjects will not be enrolled. * Central Corneal Thickness (CCT) ≤ 500. * Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil. * Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study. The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.